Date: 2014-01-13
Type of information: R&D agreement
Compound: organ-on-a-chip-based human disease models
Company: Galapagos (Belgium) Mimetas (The Netherlands)
Therapeutic area: Technology - Services
Type agreement: R&D
Action mechanism:
Disease:
Details: * On January 13, 2014, Mimetas and Galapagos have entered into a research collaboration on the development of organ-on-a-chip-based human disease models for new medicine development. The companies will collaborate to develop miniaturized 3D cell culture models that mimic specific aspects of human diseases. These models will be applied to the identification and improvement of novel compounds.
Mimetas develops organ-on-a-chip technology for testing of new medicines. Its unique microfluidic technology enables testing of new medicines in high-throughput on miniaturized organ models. These models have better predictivity compared to laboratory animals and conventional cell culture models. The Mimetas OrganoPlate™ platform allows 3D cell culture under continuous perfusion and for membrane-free co-culture, boundary and gradient formation.
Financial terms:
Latest news:
